InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Explore the detailed record of transactions filed by Brady James Aloysius. Director active across 2 companies, notably Xeris Biopharma Holdings, Inc.. Aggregated, 5 filings have been published. Split: 0 buy · 1 sell. Total volume traded: €52k. Activity tracked since 28 March 2025. The latest transaction was filed on 4 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations
Brady James Aloysius is a declarant and a Director at Xeris Biopharma Holdings, Inc. and Verona Pharma plc. The total number of filings is 5. In the recent filings we hold, the period runs from 2025-03-28 to 2026-06-05, with sales of EUR 52387 and no purchases; the stated transaction nature is Attribution.